Home › NDC Lookup › Ingredients › Sodium Citrate Dihydrate › 65197-0410-60
⚪image loading
(from DailyMed)

Emetrol Chewables Orange Sodium citrate dihydrate 230 mg Tablet, Chewable, 60-count — NDC 65197-410-60 (Billing 65197-0410-60)

by WellSpring Pharmaceutical Corporation · 1 BOTTLE in 1 BOX / 60 TABLET, CHEWABLE in 1 BOTTLE

This is a package of 60 tablets of Emetrol Chewables Orange Sodium citrate dihydrate 230 mg Tablet, Chewable from WellSpring Pharmaceutical Corporation, marketed since Jul 2023 and currently FDA-listed. It is this product's only package size.

NDC 65197-0410-60
🏷️ FDA NDC (as labeled) 65197-410-60 billing pads the product segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 65197-410-60
Product NDC 65197-410
11-digit billing NDC 65197041060
RxCUI 2002800, 2596185
UNII B22547B95K
SPL Set ID e9072f9d-d74c-4e43-bcfe-ee005577df35
Established class (EPC) Anti-coagulant; Calculi Dissolution Agent
Mechanism of action Acidifying Activity; Calcium Chelating Activity
Physiologic effect Decreased Coagulation Factor Activity
DEA schedule Non-controlled
Marketing category UNAPPROVED DRUG OTHER
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-07-01
Route ORAL
Dosage form TABLET, CHEWABLE
Substance TRISODIUM CITRATE DIHYDRATE
Quick answers
  • RxCUI (RxNorm): 2002800
Why two NDCs? The FDA registers this code as 65197-410-60 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 65197-0410-60. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Salt solutions class.

Drug family (ATC) Salt solutions
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

🧪 What is this product?

Emetrol Chewables Orange is an oral chewable tablet containing trisodium citrate dihydrate, an unapproved over-the-counter product. Trisodium citrate is commonly used in products intended to reduce stomach acid and provide relief from heartburn or acid indigestion. This product is marketed without an approved FDA application.

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
65197-0410-60 You're viewing this Main listing 1 BOTTLE in 1 BOX / 60 TABLET, CHEWABLE in 1 BOTTLE 2023-07-01 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
WALGREENS UPSET STOMACH and NAUSEA RELIEF 230 mg 00363-1834-42 WALGREENS 42 tablets — — FDA listed —
Nauzene 230 mg 52389-0242-10 Kobayashi 10 tablets — — FDA listed —
Nauzene Chewables Ginger Honey 230 mg 52389-0677-42 Kobayashi 14 tablets — — FDA listed —
Emetrol Chewables 230 mg 65197-0204-42 WellSpring 42 tablets — — FDA listed —
Emetrol Chewables Orange 230 mgthis 65197-0410-60 WellSpring 60 tablets — — FDA listed —
Emetrol Chewables Mixed Berry 230 mg 65197-0420-60 WellSpring 60 tablets — — FDA listed —
CVS Health Nausea Relief 230 mg 69842-0423-42 CVS 14 tablets — — FDA listed —
QUALITY CHOICE Nausea Relief 230 mg 83324-0300-42 QUALITY 14 tablets — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
On the market since
Jul 2023
📍
2026
Currently FDA-listed
3 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerWellSpring Pharmaceutical Corporation
Labeler code65197
First marketedJul 2023
Product typeHuman Otc Drug
Portfolio30 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 19 words ▾

Uses For the relief of nausea associated with upset/sour stomach, including that due to overindulgence in food and drink.

⏱️ Dosage and Administration 77 words ▾

Directions Adults: 2-4 tablets. Children: Consult a doctor for appropriate dosage. Chew tablets completely. Do not swallow whole Dosage may be repeated after 15 minutes, not to exceed 24 tablets in a 24-hour period unless advised by a doctor. Read all package directions and warnings before use and use only as directed. These tablets are intended for use by normally healthy persons only. Persons under 18 years of age should use only as directed by a doctor.

⚠️ Warnings 119 words ▾

Warnings Do not use if you have Hereditary Fructose Intolerance (HFI). This product contains fructose. Ask a doctor before use if you have diabetes because this product contains sugar are on a sodium-restricted diet Ask a doctor or pharmacist before use if you are taking any other medications.

This product may interact with certain prescription drugs. When using this product, do not take more than 24 tablets in a 24-hour period. Stop use and ask a doctor if nausea lasts more than two weeks or recurs frequently.

If pregnant or breast-feeding , ask a health professional before use. In case of overdose, get medical help or contact a Poison Control Center right away. Keep out of reach of children

🧪 Active Ingredient 8 words ▾

Active ingredients Sodium citrate dihydrate USP 230 mg

🧪 Inactive Ingredients 14 words ▾

Inactive ingredients dextrose, flavor, fructose, hydroxypropyl cellulose, magnesium stearate, maltodextrin, silica, sodium carboxymethylcellulose, sucralose.

🎯 Purpose 4 words ▾

Purpose Upset stomach reliever

📄 Do Not Use 14 words ▾

Do not use if you have Hereditary Fructose Intolerance (HFI). This product contains fructose.

📄 Ask a Doctor Before Use If 19 words ▾

Ask a doctor before use if you have diabetes because this product contains sugar are on a sodium-restricted diet

📄 Stop Use and Ask a Doctor If 16 words ▾

Stop use and ask a doctor if nausea lasts more than two weeks or recurs frequently.

🤰 If Pregnant or Breast-Feeding 26 words ▾

If pregnant or breast-feeding , ask a health professional before use. In case of overdose, get medical help or contact a Poison Control Center right away.

📄 Keep Out of Reach of Children 6 words ▾

Keep out of reach of children

📄 Package Label / Principal Display Panel 76 words ▾

PACKAGE LABEL # 1 Pharmacist Recommended New Non-Drowsy Emetrol Chewable Rapid Nausea Relief Treats the source of Nausea* *Due to overindulgence in food and drink Powerful, Soothing Relief Orange Flavor 60 Chewable Tablets Emetrol Chewables Orange CT20410B Side Panels Emetrol Chewables Rapid Nausea Relief Non-Drowsy Treats the source of Nausea* Specially Formulated for Adults Great-tasting Lemon Chewables *Due to overindulgence in food and drink Emetrol Chewables relieves stomach discomfort with: No Acetaminophen No Aspirin No Caffeine

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

About this NDC listing & data coverage

Over-the-counter (OTC) product Marketed without an FDA application

Listed without an FDA application

This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Drug Other". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by WellSpring Pharmaceutical Corporation. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
WellSpring Pharmaceutical Corporation is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.